Mylan prices its generic remdesivir in India at $64 per 100 mg vial (updated)

Syngene International

06/07/2020 14:16

(Adds details on remdesivir pricing, supply concerns over
treatment)
    BENGALURU, July 6 (Reuters) - Mylan NV  MYL.O  said on
Monday it would launch a generic version of Gilead Sciences
Inc's  GILD.O  COVID-19 antiviral remdesivir in India at 4,800
rupees ($64.31), about 80% below the price tag on the drug for
wealthy nations.
    California-based Gilead has signed licensing deals with
several generic drugmakers in an effort to make remdesivir
available in 127 developing countries.
    Last month, two Indian drugmakers, Cipla Ltd  CIPL.NS  and
privately-held Hetero Labs Ltd, also launched generic versions
of the treatment. Cipla will price its version, Cipremi, at less
than 5,000 rupees, while Hetero has priced Covifor at 5,400
rupees.  urn:newsml:reuters.com:*:nL4N2E02NP urn:newsml:reuters.com:*:nL4N2E12JP
    Gilead, last week, priced remdesivir at $2,340 per patient
for rich nations and agreed to send nearly all of its supply of
the drug to the United States over the next three months.
    Mylan's price was for 100 mg vials, but it was not
immediately clear how many of those vials would be required for
a full treatment course. Gilead has said for a five-day
treatment course, a patient would need six vials of remdesivir.
    Remdesivir is in high demand after the
intravenously-administered medicine helped to shorten hospital
recovery times in a clinical trial but there has been concerns
over its supply. 
    Mylan said it would manufacture remdesivir in India at its
injectables facilities and was working toward expanding access
for patients in the 127 low- and middle-income countries where
it is licensed by Gilead Sciences to do so.     
    The Drug Controller General of India (DCGI) approved Mylan's
remdesivir version, to be called Desrem, for the treatment of
suspected or laboratory confirmed severe incidences of COVID-19
in adults and children, the company said in a statement https://prn.to/2By83B9.
    India is the world's third worst hit nation, with the number
of coronavirus cases surging to 697,413 on Monday.  urn:newsml:reuters.com:*:nL4N2ED12J
    
($1 = 74.6356 Indian rupees)

    <^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
UPDATE 5-Gilead prices COVID-19 drug remdesivir at $2,340 per
patient in developed nations     urn:newsml:reuters.com:*:nL4N2E62WK
WRAPUP 1-World takes stock of COVID-19 drug remdesivir after
U.S. snaps up supplies     urn:newsml:reuters.com:*:nL8N2E85LC
FACTBOX-Worldwide coronavirus cases cross 11.46 million, death
toll at 533,224     urn:newsml:reuters.com:*:nL4N2AY3AS
FACTBOX-Countries where remdesivir is approved or supported for
treating COVID-19     urn:newsml:reuters.com:*:nL4N2EA2LZ
    ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^>
 (Reporting by Anuron Kumar Mitra and Ankur Banerjee in
Bengaluru; Editing by Rashmi Aich and Sweta Singh)
 ((AnuronKumar.Mitra@thomsonreuters.com; +91 99863 58469;))